An injectable, in situ forming and NIR-responsive hydrogel persistently reshaping tumor microenvironment for efficient melanoma therapy.

ABSTRACT:

Background

Melanoma is a highly aggressive form of skin cancer with increasing incidence and mortality rates. Chemotherapy, the primary treatment for melanoma, is limited by hypoxia-induced drug resistance and suppressed immune response at the tumor site. Modulating the tumor microenvironment (TME) to alleviate hypoxia and enhance immune response has shown promise in improving chemotherapy outcomes.

Methods

In this study, a novel injectable and in situ forming hydrogel named MD@SA was developed using manganese dioxide (MnO₂) nanosheets pre-loaded with the chemotherapy drug doxorubicin (DOX) and mixed with sodium alginate (SA). The sustainable drug delivery, oxygen generation ability, and photothermal property of MD@SA hydrogel were characterized. The therapeutic e

SUBMITTER: Zhang H 

PROVIDER: S-EPMC10659094 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature